Drug design: 4-thiazolidinones applications. Part 1. Synthetic routes to the drug-like molecules


  • Roman Lesyk Danylo Halytsky Lviv National Medical University, Ukraine




Structure-based drug design, 5-Ene-4-thiazolidinones, Thiopyrano[2,3-d]thiazoles, biological activity, SAR analysis, Michael acceptors


4-Thiazolidinones, as examples of privileged scaffolds, have been the focus of medicinal chemistry since 60th. Among them, 5-substituted thiazolidinones with a C5 exocyclic bond (5-ene derivatives) are of special interest due to chemical characteristics and pharmacological profiles, possessing anticancer, antimicrobial, and antiviral properties, as well as being high-affinity ligands to a number of biological targets. A new medicinal chemistry trend claims that the aforementioned compounds are frequent hitters or pan assay interference compounds, which are useless because of the possible low selectivity. This is argued by the Michael acceptor property of 5-ene-4-thiazolidinones, which is actively discussed in the literature and requires further investigation. Based on SAR analysis, the main vectors for the design of 5-ene-4-thiazolidinone-based molecules were proposed: complication of C5 fragment; introduction of the substituents in the N3 position; synthesis of isosteric heterocycles; combination with other pharmacologically attractive fragments; annealing of thiazolidinone core; utilisation of 5-ene-thiazolidinones in synthesis of other compounds. The affinity of 5-ene-4-thiazolidinones toward various targets can be regarded as an advantage in polypharmacological approaches. Michael acceptors are considered as the “new old tool” for new drug creation, especially anticancer agents. One of the possible solutions within privileged substructure-based diversity-oriented synthesis is the fixation of 5-ene-4-thiazolidinone fragment in the fused heterocycles, for example, thiopyrano[2,3-d]thiazoles obtained from 5-ene-thiazolidinones.


Download data is not yet available.


Lesyk R, Zimenkovsky B. 4-Thiazolidones: Centenarian History, Current Status and Perspectives for Modern Organic and Medicinal Chemistry. Curr Org Chem. 2004; 8(16): 1547-1578.

Havrylyuk D, Zimenkovsky B, Lesyk R. Synthesis, biological activity of thiazolidinone bearing indoline moiety and isatin based hybrids. Mini Rew Org Chem. 2015; 12(1): 66-87.

Havrylyuk D, Roman O, Lesyk R. Synthetic approaches, structure activity relationship and biological applications for pharmacologically attractive pyrazole/pyrazoline–thiazolidine–based hybrids. Eur J Med Chem. 2016; 113: 145-166.

Tripathi AC, Gupta SJ, Fatima GN, Sonar K, Verma A, Saraf SK. 4-Thiazolidinones: the advances continue… Eur J Med Chem. 2014; 72: 52–77.

Tomasic T, Mašic LP. Rhodanine as a privileged scaffold in drug discovery. Curr Med Chem. 2009; 16: 1596–1629.

Verma A, Saraf SK. 4-Thiazolidinone – a biologically active scaffold. Eur J Med Chem. 2008; 43: 897–905.

Tomasic T, Mašic LP. Rhodanine as a scaffold in drug discovery: a critical review of its biological activities and mechanisms of target modulation, Expert Opin Drug Discovery. 2012; 7: 549-560.

Mendgen T, Steuer C. Klein C. Privileged scaffolds or promiscuous binders: a comparative study on rhodanines and related heterocycles in medicinal chemistry. J Med Chem. 2012; 55: 743–753.

Baell JB. Observations on screening-based research and some concerning trends in the literature. Future Med Chem. 2010; 2: 1529-1546.

Baell JB, Holloway GA. New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. J Med Chem. 2010; 53: 2719-2740.

Baell JB, Walters MA. Chemical con artists foil drug discovery. Nature. 2014; 513: 481-483.

Kaminskyy D, Kryshchyshyn A, Lesyk R. 5-Ene-4-thiazolidinones - An efficient tool in medicinal chemistry. Eur J Med Chem. 2017; 140: 542-594.

Kaminskyy D, Kryshchyshyn A, Lesyk R. Recent developments with rhodanine as a scaffold for drug discovery. Expert Opin Drug Discovery. 2017; 12(12): 1233-1252.

Lesyk RB, Zimenkovsky BS, Kaminskyy DV, Kryshchyshyn AP, Havrylyuk DYa, Atamanyuk DV, et al. Thiazolidinone motif in anticancer drug discovery. Experience of DH LNMU medicinal chemistry scientific group. Biopolym Cell. 2011; 27: 107–117.

Kryshchyshyn A, Roman O, Lozynskyi A, Lesyk R. Thiopyrano[2,3-d]thiazoles as new efficient scaffolds in medicinal chemistry. Sci Pharm. 2018; 86(2): 26.

Mosula L, Zimenkovsky B, Havrylyuk D, Missir A-V, Chirita IC, Lesyk R. Synthesis and antitumor activity of novel 2-thioxo-4-thiazolidinones with benzothiazole moieties. Farmacia. 2009; 57(3): 321-330.

Havrylyuk D, Mosula L, Zimenkovsky B, Vasylenko O, Gzella A, Lesyk R. Synthesis and anticancer activity evaluation of 4-thiazolidinones containing benzothiazole moiety. Eur J Med Chem. 2010; 45(11): 5012-5021.

Kaminskyy D, Hartog GJM, Wojtyra M, Lelyukh M, Gzella A, Bast A, Lesyk R. Antifibrotic and anticancer action of 5-ene amino/iminothiazolidinones. Eur J Med Chem. 2016; 112: 180-195.

Senkiv J, Finiuk N, Kaminskyy D, Havrylyuk D, Wojtyra M, Kril I, et al. 5-Ene-4-thiazolidinones induce apoptosis in mammalian leukemia cells. Eur J Med Chem. 2016; 117: 33-46.

Wojtyra MN, Lesyk RB. Synthesis of 3-pyridyl-substituted 4-thiazolidinones as potential biologically active compounds. Pharmaceutical Review. 2017; 1: 11-16 (in Ukrainian).

Wojtyra MN, Lesyk RB, Zimenkovsky BS, Grellier P. (Z)-(5-[5-(3,5-diaryl-4,5-dihydropyrazol-1-yl-methylidene)-3-(pyridine-3-yl)-2-thioxothiazolidin-4-ones exhibiting antitrypanosomal action. Patent UA 119822. Disclosure 18.04.2017. Published 10.10.2017. Bull. №19 (in Ukrainian).

Holota S, Kryshchyshyn A, Derkach H, Trufina Y, Demchuk I, Gzella A, et al. Synthesis of 5-enamine-4-thiazolidinone derivatives with trypanocidal and anticancer activity. Bioorg Chem. 2019; 86: 126-136.

Lelyukh M, Havrylyuk D, Lesyk R. Synthesis and anticancer activity of isatin, oxadiazole аnd 4-thiazolidinone based conjugates. Chem Chem Technol. 2015; 9(1): 29-36.

Kaminskyy D, Khyluk D, Vasylenko O, Zaprutko L, Lesyk R. A facile synthesis and anticancer activity evaluation of spiro[thiazolidinone-isatin] conjugates. Sci Pharm. 2011; 4: 763-777.

Havrylyuk D, Zimenkovsky B, Vasylenko O, Zaprutko L, Gzella A, Lesyk R. Synthesis of novel thiazolone-based compounds containing pyrazoline moiety and evaluation of their anticancer activity. Eur J Med Chem. 2009; 44(4): 1396-1404.

Havrylyuk DYa, Zimenkovsky BS, Vasylenko OM, Lesyk RB. Synthesis and study of antiviral activity of thiazolone derivatives with pyrazoline moiety in molecules. Journal of Organic and Pharmaceutical Chemistry. 2009; 7(1): 42-47 (in Ukrainian).

Havrylyuk D, Zimenkovsky B, Vasylenko O, Gzella A, Lesyk R. Synthesis of New 4-Thiazolidinone-, Pyrazoline-, and Isatin-Based Conjugates with Promising Antitumor Activity. J Med Chem. 2012; 55: 8630-8641.

Kryshchyshyn A, Kaminskyy D, Karpenko O, Gzella A, Grellier P, Lesyk R. Thiazolidinone/thiazole based hybrids – New class of antitrypanosomal agents. Eur J Med Chem. 2019; 174: 292-308.

Kaminskyy D, Bednarczyk-Cwynar B, Vasylenko O, Kazakova O, Zimenkovsky B, Zaprutko L, Lesyk R. Synthesis of new potential anticancer agents based on 4-thiazolidinone and oleanane scaffolds. Med Chem Res. 2012; 21(11): 3568-3580.

Komarista ID. Synthesis, transformations and biological activity of some azolidones and their condensed derivatives. DSc Thesis, I.M. Sechenov First State Medical Institute, Moscow, USSR, 1989.

Komaritsa ID, Baranov SN, Grischuk AP. 4-Thiazolidines, derivatives and analogs. Chem Heterocycl Comp. 1967; 3: 533-534.

Plevachuk NE, Komaritsa ID. A study of azolidones and their derivatives. Chem Heterocycl Comp. 1970; 6: 144-145.

Grishchuk AP, Komaritsa ID, Baranov SN. 4-Thionazolidones, derivatives and analogs. Chem Heterocycl Comp. 1966; 2: 541-543.

Lozynskyi A, Zimenkovsky B, Lesyk R. Synthesis and Anticancer Activity of New Thiopyrano[2,3-d]thiazoles Based on Cinnamic Acid Amides. Sci Pharm. 2014; 82(4): 723-733.

Lozynskyi A, Zasidko V, Atamanyuk D, Kaminskyy D, Derkach H, Karpenko O,et al. Synthesis, antioxidant and antimicrobial activities of novel thiopyrano[2,3-d]thiazoles based on aroylacrylic acids. Mol Divers. 2017; 21(2): 427-436.

Lozynskyi A, Zimenkovsky B, Nektegayev I, Lesyk R. Arylidene pyruvic acids motif in the synthesis of new thiopyrano[2,3-d]thiazoles as potential biologically active compounds Heterocycl Commun. 2015; 21(1): 55-59.

Zelisko N, Atamanyuk D, Ostapiuk Y, Bryhas A, Matiychuk V, Gzella A, Lesyk R. Synthesis of fused thiopyrano[2,3-d][1,3]thiazoles via hetero-Diels–Alder reaction related tandem and domino processes. Tetrahedron. 2015; 71(50): 9501-9508.

Zelisko N, Atamanyuk D, Vasylenko O, Bryhas A, Matiychuk V, Gzella A, Lesyk R. Crotonic, cynnamic and propiolic acids motifs in the synthesis of thiopyrano[2,3-d][1,3]thiazoles via hetero-Diels-Alder reaction and related tandem processes. Tetrahedron. 2014; 70(3): 720-729.

Lozynskyi A, Golota S, Zimenkovsky B, Atamanyuk D, Gzella A, Lesyk R. Synthesis, anticancer and antiviral activities of novel thiopyrano[2,3-d]thiazole-6-carbaldehydes. Phosphorus Sulfur Silicon Relat Elem. 2016; 191(9): 1245-1249.

Kryshchyshyn AP, Atamanyuk DV, Kaminskyy DV, Grellier P, Lesyk RB. Investigation of anticancer and anti-parasitic activity of thiopyrano[2,3-d]thiazoles bearing norbornane moiety. Biopolym Cell. 2017; 33(3): 183-205.

Lesyk R, Zimenkovsky B, Atamanyuk D, Jensen F, Kiec-Kononowicz K, Gzella A. Anticancer thiopyrano[2,3-d]thiazol-2-ones with norbornane moiety. Synthesis, cytotoxicity, physico-chemical properties, and computational studies. Bioorg Med Chem. 2006; 14: 5230-5240.

Atamanyuk D, Zimenkovsky B, Lesyk R. Synthesis and anticancer activity of novel thiopyrano[2.3-d]thiazole-based compounds containing norbornane moiety. J Sulfur Chem. 2008; 29(2): 151-162.

Lozynskyi A, Zimenkovsky B, Karkhut A, Polovkovych S, Gzella AK, Lesyk R. Application of the 2(5H)furanone motif in the synthesis of new thiopyrano[2,3-d]thiazoles via the hetero-Diels–Alder reaction and related tandem processes. Tetrahedron Lett. 2016; 57(30): 3318-3321.

Zelisko N, Karpenko O, Muzychenko V, Gzella A, Grellier P, Lesyk R. trans-Aconitic acid-based hetero-Diels-Alder reaction in the synthesis of thiopyrano[2,3-d][1,3]thiazole derivatives. Tetrahedron Lett. 2017; 58(18): 1751-1754.

Atamanyuk D, Zimenkovsky B, Atamanyuk V, Nektegayev I, Lesyk R. Synthesis and Biological Activity of New Thiopyrano[2,3-d]thiazoles Containing a Naphthoquinone Moiety. Sci Pharm. 2013; 81(2): 423-436.

Atamanyuk D, Zimenkovsky B, Atamanyuk V, Lesyk R. 5-Ethoxymethylidene-4-thioxo-2-thiazolidinone as versatile building block for novel bio-relevant small molecules with thiopyrano[2,3-d][1,3]thiazole core. Synth Commun. 2014; 44(2): 237-244.

Kaminskyy D, Vasylenko O, Atamanyuk D, Gzella A, Lesyk R. Isorhodanine and thirhodanine motifs in the synthesis of fused thiopyrano[2,3-d][1,3]thiazoles. SYNLETT. 2011; 10: 1385-1388.

Zelisko NI, Finiuk NS, Shvets VM, Medvid YO, Stoika RS, Lesyk RB. Screening of spiro-substituted thiopyrano[2,3-d]thiazoles for their cytotoxic action on tumor cells. Biopolym Cell. 2017; 33(4): 282-290.

Zelisko N, Atamanyuk D, Vasylenko O, Grellier P, Lesyk R. Synthesis and antitrypanosomal activity of new 6,6,7-trisubstituted thiopyrano[2,3-d][1,3]thiazoles. Bioorg Med Chem Lett. 2012; 22(23): 7071-7074.

Lozynskyi A, Zimenkovsky B, Gzella AK, Lesyk R. Arylidene pyruvic acids motif in the synthesis of new 2H,5H-chromeno[4’,3’:4,5]thiopyrano[2,3-d]thiazoles via tandem hetero-Diels-Alder-hemiacetal reaction. Synth Commun. 2015; 45(19): 2266-2270.

Matiychuk V, Lesyk R, Obushak M, Gzella A, Atamanyuk D, Ostapiuk Y, Kryshchyshyn A. A new domino-Knoevenagel-hetero-Diels-Alder reaction. Tetrahedron Lett. 2008; 49(31): 4648-4651.

Structure of target 5-ene-4-thiazolidinones



How to Cite

Lesyk R. Drug design: 4-thiazolidinones applications. Part 1. Synthetic routes to the drug-like molecules. JMS [Internet]. 2020Mar.31 [cited 2020May26];89(1):e406. Available from: https://jms.ump.edu.pl/index.php/JMS/article/view/406



Review Papers